Please assess the completion status of the following clinical trial:

Trial Title: Aspirin in Preventing Colorectal Cancer in Patients at Increased Risk of Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Criteria:~* No active or metastatic cancer within the past 6 months~* Scheduled to undergo colonoscopy for colonic neoplasia surveillance~* Hemoglobin \>= 12.0 g/dL~* Platelet count \>= 120,000/mm\^3~* AST or ALT =\< 1.5 times upper limit of normal (ULN)~* Alkaline phosphatase =\< 1.5 times ULN~* Bilirubin =\< 1.5 times ULN~* BUN =\< 40 mg/dL~* Glomerular filtration rate \>= 45 mL/min~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No coagulopathy~* No anemia~* No history of peptic ulcer disease or gastrointestinal hemorrhage~* No history of cerebrovascular accident~* No uncontrolled hypertension~* No history of intolerance or allergy to aspirin or to NSAIDs~* No liver disease as manifested by signs or symptoms of cirrhosis~* No endoscopic or radiographic evidence of portal hypertension~* No active colitis by endoscopy~* No history of inflammatory bowel disease~* No requirement for aspirin as medical therapy (i.e., post-myocardial infarction or transient ischemic attack)~* No untreated helicobacter pylori infection~* History of significant colonic neoplasia, defined as 1 of the following:~  * Adenoma within the past 6 years~ * Colorectal cancer within the past 6 years~ * Known adenoma on present exam~ * Histologically confirmed polyps seen on imaging~* INR =\< 1.5~* At least 6 months since prior cancer treatment~* No other concurrent acetylsalicylic acid (aspirin)-containing products or non-steroidal anti-inflammatory drugs (NSAIDs)~* No concurrent systemic corticosteroids~* No other concurrent anticoagulants or antiplatelet agents~* No concurrent investigational drugs

- Gender: ALL
- Minimum Age: None
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive oral acetylsalicylic acid (aspirin) once daily.
- Arm II (Type: PLACEBO_COMPARATOR): Patients receive oral placebo once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).